The in vitro screening core, overseen by Drs Nancy Connell and Barry Kreiswirth, will provide comprehensive screening services for susceptibility and cytotoxicity determination for candidate compounds provided by the project directors. The standard wild type bacterial strains represent Mycobacterium tuberculosis (both actively growing and non-replicative), other pathogenic mycobacterial species, the ESKAPE pathogens (Enterococcus faecium. Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) and bacterial Select Agents (Bacillus anthracis, Francisella tularensis. Yersinia pestis, Burkholderia mallei, Burkholderia pseudomallei, Rickettsia prowazekii, and Coxiella burnetii). In addition, the Public Health Research Institute has extensive collections of bacterial and fungal pathogens in collaboration with private, public and VA hospitals in the New York/New Jersey Metropolitan area, as well as hospitals throughout the world. The bacterial strain collection of drug susceptible and drug resistant organisms is derived largely from bloodstream, soft-tissue, burn, wound, pustules, and respiratory fluids specimens. Finally, the in vitro screening core will provide cytotoxicity screening in mammalian cells (VERO, J774.1, RAW, THP1) and intracellular antibiotic efficacy studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI109713-04
Application #
9243967
Study Section
Special Emphasis Panel (ZAI1-LR-M)
Project Start
Project End
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
4
Fiscal Year
2017
Total Cost
$511,142
Indirect Cost
$189,669
Name
Rutgers University
Department
Type
Domestic Higher Education
DUNS #
078795851
City
Newark
State
NJ
Country
United States
Zip Code
07103
Becka, Scott A; Zeiser, Elise T; Barnes, Melissa D et al. (2018) Characterization of the AmpC ?-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother 62:
Hover, Bradley M; Kim, Seong-Hwan; Katz, Micah et al. (2018) Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nat Microbiol 3:415-422
Barnes, Melissa D; Bethel, Christopher R; Alsop, Jim et al. (2018) Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam. Antimicrob Agents Chemother 62:
Kumar, Pradeep; Capodagli, Glenn C; Awasthi, Divya et al. (2018) Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA. MBio 9:
Nukaga, Michiyoshi; Papp-Wallace, Krisztina M; Hoshino, Tyuji et al. (2018) Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam. Antimicrob Agents Chemother 62:
Becka, Scott A; Zeiser, Elise T; Marshall, Steven H et al. (2018) Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans. Diagn Microbiol Infect Dis 92:253-258
Vila-Farres, Xavier; Chu, John; Ternei, Melinda A et al. (2018) An Optimized Synthetic-Bioinformatic Natural Product Antibiotic Sterilizes Multidrug-Resistant Acinetobacter baumannii-Infected Wounds. mSphere 3:
Papp-Wallace, Krisztina M; Barnes, Melissa D; Alsop, Jim et al. (2018) Relebactam Is a Potent Inhibitor of the KPC-2 ?-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrob Agents Chemother 62:
Lane, Thomas; Russo, Daniel P; Zorn, Kimberley M et al. (2018) Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. Mol Pharm 15:4346-4360
Papp-Wallace, Krisztina M; Nguyen, Nhu Q; Jacobs, Michael R et al. (2018) Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using ?-Lactamase Inhibitors and ?-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. J Med Chem 61:4067-4086

Showing the most recent 10 out of 23 publications